Exelixis Proves Being Second Can Work Out Well

Exelixis (NASDAQ:EXEL) is proving that sometimes being second-best can work out just fine, especially when you're in the business of treating a disease like kidney cancer -- a condition for which no cure has been found, so patients' cancers will eventually progress on the first drug they take. Bristol-Myers Squibb's (NYSE:BMY) Opdivo and Yervoy combination may grab many of those patients initially, but 90% of those who progress on that regimen are moving on to Exelixis' Cabometyx.